Moderna, Inc. (MRNA)
Why Moderna (MRNA) Dipped More Than Broader Market Today
The latest trading day saw Moderna (MRNA) settling at $121.25, representing a -1.02% change from its previous close.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ:MRNA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Moderna co-founder Robert Langer to step down from vaccine maker's board
Robert Langer, co-founder and a key figure behind Moderna's scientific success, will step down from the vaccine maker's board on Aug. 5, the company said on Tuesday.
David Rubenstein Joins Moderna's Board of Directors
Co-Founder and Co-Chairman of The Carlyle Group brings multi-industry investor experience and global policy expertise, replacing retiring director Stephen Berenson Co-founder and director Robert Langer also to retire from the Moderna Board; recruitment efforts ongoing for his replacement CAMBRIDGE, MA / ACCESSWIRE / July 23, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that David M. Rubenstein, Co-Founder and Co-Chairman of The Carlyle Group, will join Moderna's Board of Directors, effective August 5, 2024.
Moderna (MRNA) Stock Rises 22% YTD: Time to Buy the Stock?
Shares of Moderna (MRNA) continue to soar thanks to the encouraging development of its non-COVID pipeline. The company's potential product launches over the next few years make it worth looking at.
2 Growth Stocks Down 25% to Buy Right Now
Starbucks is struggling in the short term but has a clear path to improved results. Moderna can expect increased revenue after a new vaccine it developed received FDA approval.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ:MRNA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Is Moderna Stock a Buy?
Moderna's performance slowed as the pandemic's worst effects began to wane. The company is notching important clinical and regulatory wins.
Is Moderna Stock A Buy As It Faces Off With Pfizer, GSK In The Massive RSV Market?
Is Moderna stock a buy after unveiling promising results for its Pfizer- and GSK-rivaling RSV vaccine? Is MRNA stock a buy now?
Moderna to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update.
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why
Moderna (MRNA) reachead $116.07 at the closing of the latest trading day, reflecting a -0.33% change compared to its last close.
3 Healthcare Stocks to Sell in July Before They Crash & Burn
The outlook of many healthcare stocks is quite positive at this point. That's partly because many large investors have shunned the sector, since they believe that it is destined to produce horrible returns as long as interest rates remain elevated.
